TIEKF yields 1.95% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, TIEKF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TIEKF + PFE for your $10,000?
TIE Kinetix N.V. develops, distributes, and sells software and services in the Netherlands, the United States, Germany, and France. The company offers digital supply chain solutions; and electronic document exchange solutions, such as electronic data interchange (EDI)-2-FLOW, PDF-2-FLOW, and PORTAL-2-FLOW, as well as E-Archiving. It also provides software as a service solution for exchanging business documents to companies, governmental institutions, and trading partners and suppliers, as well as artificial intelligence-powered onboarding services. In addition, the company offers AP automation solutions for buyers and suppliers to engage in smart business exchanges; pre-built connectors and standardized API integrations to connect to ERP or other systems; compliance solutions; value added network services, which enables trading partners to communicate and exchange business documents in various formats real-time using various communication protocols; electronic invoicing solutions; and consultancy services. Further, it provides FLOW Partner Automation platform that combines supply chain integration solutions, such as EDI/XML, PDF conversion, and supplier portal, as well as analytics data and dashboards for users. The company offers its solutions to business services, industry and home improvement, telecom, banking and insurance, food industry and food retail, non-food, consumer electronics, transport and logistics, office supplies, automotive, medical, and others markets directly, as well as through a network of distribution partners. TIE Kinetix N.V. was founded in 1987 and is headquartered in Breukelen, the Netherlands.
Full TIEKF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.